Inactive Instrument

Clinigen Group plc

CLIN

GB00B89J2419

Clinigen Group plc Announces Resignation of Chris Rigg as Director

December 06, 2017 at 12:30 pm IST

Clinigen Group plc announced that Chris Rigg has resigned with immediate effect as a director to seek a CEO role elsewhere.

Latest news about Clinigen Group plc

Clinigen Launches NaviGATE an Educational Programme for Rare Disease Patients and Organizations	12/23/12	CI
CNX Therapeutics Limited acquired Cardioxane® (dexrazoxane), Savene® (dexrazoxane), Totect® (dexrazoxane) and Ethyol®, four cancer support therapies from Clinigen Limited.	10/23/10	CI
Clinigen Limited Reports Earnings Results for the Full Year Ended June 30, 2022	09/23/09	CI
Adragos Pharma GmbH completed the acquisition of Lamda Laboratories S.A. from Clinigen Limited.	03/23/03	CI
Adragos Pharma GmbH signed a definitive agreement to acquire Lamda Laboratories S.A. from Clinigen Limited.	20/23/20	CI
Iovance Biotherapeutics, Inc. entered into a definitive agreement to acquire Worldwide rights of Proleukin of Clinigen Limited for approximately £210 million.	23/23/23	CI
Clinigen Group plc acquired Drug Safety Navigator, LLC.	31/22/31	CI
Clinigen Notes Results from the MIROCALS Trial Investigating Low Dose Proleukin® (Aldesleukin) in Patients with Amyotrophic Lateral Sclerosis	08/22/08	CI
Clinigen Group plc agreed to acquire Drug Safety Navigator, LLC.	29/22/29	CI
Clinigen Expands US Site Capacity in Response to Growing Demand for Clinical Supplies Management Services	24/22/24	CI
Triton Funds Company Completes Takeover Of Clinigen	04/22/04	MT
Triton Fund V SCSP, Triton Fund V L.P., Triton Fund V F&F No. 5 SCSp, Triton Fund V F&F No.3 L.P., Triton Fund V F&F L.P., Triton Fund V F&F No. 2 L.P., Triton Fund V F&F 4 SCSp and Triton C Investment A L.P., managed by Triton completed the acquisition of Clinigen Group plc.	04/22/04	CI
UK's High Court Approves Clinigen's Takeover	31/22/31	MT
Clinigen's Fiscal H1 Profit Sinks As Sales, Administrative Costs Rise	23/22/23	MT
Clinigen Group plc Reports Earnings Results for the Half Year Ended December 31, 2021	23/22/23	CI
Scentre Group CEO/Managing Director to Step Down End-September; Shares Fall 5%	23/22/23	MT
Scentre Signals Higher Distribution, Faster Earnings Growth in Fiscal Year 2022	23/22/23	DJ
Clinigen Expects to Complete $1.8 Billion Sale to Triton in Early April	16/22/16	MT
Clinigen Group plc Signs Distribution Agreement with Deciphera Pharmaceuticals	09/22/09	CI
Clinigen Group Declares the Voting Results	08/22/08	CI
Clinigen Group plc Issues Open Letter to the Shareholders	21/22/21	CI
Clinigen Postpones Court, General Meetings following Increased Takeover Offer	18/22/18	MT
Global markets live: Credit Suisse, Unilever, Pfizer, Volkswagen, Triton...	17/22/17
UK's Clinigen agrees to sweetened $1.8 billion Triton take-private deal	17/22/17	RE
Clinigen Receives Sweetened $1.8 Billion Takeover Bid From Triton	17/22/17	MT

Clinigen Group plc is a United Kingdom-based pharmaceutical services and products company. The Company's principal activities are focused on providing healthcare professionals (HCPs) and their patients with access to medicines. It operates through two segments: Services and Products. Its product brands include ACETYLCYSTEINE, COLECALCIFEROL, CARDIOXANE, ERWINASE / ERWINAZE, ETHYOL, FOLIC ACID COLONIS, FOSCAVIR, GABAPENTIN COLONIS, GLYCOPYRRONIUM BROMIDE, ILOPROST, IMUKIN / IMMUKIN / IMMUKINE, METFORMIN COLONIS, NORTRIPTYLINE COLONIS, PROLEUKIN and SAVENE, among others. The services provided by the Company includes clinical supplies management, managed access programs, real world data and medical science liaison (MSL). It operates in locations across North America, Europe, Africa, Japan and Asia Pacific. Its subsidiaries include Clinigen Healthcare B.V., Clinigen Clinical Trials Limited, Link Healthcare Singapore Pte. Limited and Clinigen South Africa (Pty) Limited, among others.

Sector

More about the company